Inogen Inc. Files 8-K on Financials
Ticker: INGN · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1294133
| Field | Detail |
|---|---|
| Company | Inogen Inc (INGN) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, financials
Related Tickers: INGN
TL;DR
Inogen filed an 8-K for financial updates, no major news yet.
AI Summary
On January 13, 2025, Inogen Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or significant events were detailed in the provided excerpt.
Why It Matters
This filing indicates Inogen Inc. is providing updates on its financial performance and condition to the SEC, which is important for investors to monitor the company's health.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification and does not contain specific financial results or forward-looking statements that would indicate immediate risk.
Key Players & Entities
- Inogen Inc. (company) — Registrant
- January 13, 2025 (date) — Date of earliest event reported
- 859 Ward Drive, Goleta, California 93111 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Inogen Inc.?
The primary purpose of this 8-K filing is to report on Inogen Inc.'s Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on January 13, 2025.
What is Inogen Inc.'s principal executive office address?
Inogen Inc.'s principal executive office is located at 859 Ward Drive, Goleta, California 93111.
What is the Commission File Number for Inogen Inc.?
The Commission File Number for Inogen Inc. is 001-36309.
What is the SIC code for Inogen Inc.?
The Standard Industrial Classification (SIC) code for Inogen Inc. is 3842, which pertains to Orthopedic, Prosthetic & Surgical Appliances & Supplies.
Filing Stats: 558 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2025-01-13 16:06:07
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value INGN The Nasdaq Stock Mar
Filing Documents
- ingn-20250113.htm (8-K) — 41KB
- ingn-ex99_1.htm (EX-99.1) — 18KB
- img132417817_0.jpg (GRAPHIC) — 3KB
- 0000950170-25-004824.txt ( ) — 175KB
- ingn-20250113.xsd (EX-101.SCH) — 23KB
- ingn-20250113_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On January 13, 2025, Inogen, Inc. (the "Company") issued a press release reporting preliminary, unaudited revenue results for the fourth quarter and full year ended December 31, 2024. The amounts included in the press release are preliminary, have not been audited and are subject to change upon completion of the Company's audited financial statements for the year ended December 31, 2024. Additional information and disclosures would be required for a more complete understanding of the Company's financial position and results of operations as of December 31, 2024. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report 8-K. The information set forth under this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release, dated January 13, 2025 104 The cover page of this Current Report on Form 8-K, formatted in Inline XBRL
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. INOGEN, INC. Date: January 13, 2025 By: /s/ Michael Bourque Michael Bourque Executive Vice President Chief Financial Officer Treasurer (Principal Accounting and Financial Officer)